Literature DB >> 17594994

Outcomes of buprenorphine maintenance in office-based practice.

Stephen Magura1, Stephen J Lee, Edwin A Salsitz, Andrew Kolodny, Susan D Whitley, Tanaquil Taubes, Randy Seewald, Herman Joseph, Deborah J Kayman, Chunki Fong, Lisa A Marsch, Andrew Rosenblum.   

Abstract

Buprenorphine is an efficacious treatment for opioid dependence recently approved for office-based medical practice. The purpose of the study was to describe the background characteristics, treatment process, outcomes and correlates of outcomes for patients receiving buprenorphine maintenance in "real world" office-based settings in New York City, without employing the many patient exclusion criteria characterizing clinical research studies of buprenorphine, including absence of co-occurring psychiatric and non-opioid substance use disorders. A convenience sample of six physicians completed anonymous chart abstraction forms for all patients who began buprenorphine induction or who transferred to these practices during 2003-2005 (N = 86). The endpoint was the patient's current status or status at discharge from the index practice, presented in an intent-to-treat analysis. The results were: male (74%); median age (38 yrs); White, non-Hispanic (82%); employed full-time, (58%); HCV+ (15%); substance use at intake: prescription opioids (50%), heroin (35%), non-opioids (49%); median length of treatment (8 months); median maintenance dose (15 mg/day); prescribed psychiatric medication (63%). The most frequent psychiatric disorders were: major depression, obsessive-compulsive and other anxiety, bipolar. At the endpoint: retained in the index practice (55%); transferred to other buprenorphine practice (6%); transferred to other treatment (7%); lost to contact or out of any treatment (32%). Outcomes were positive, in that 2/3 of patients remained in the index practice or transferred to other treatment. Patients living in their own home or misusing prescription opioids (rather than heroin) were more likely, and those employed part-time were less likely, to be retained in the index practice. At the endpoint, 24% of patients were misusing drugs or alcohol. Co-occurring psychiatric disorders and polysubstance abuse at intake were common, but received clinical attention, which may explain why their effect on outcomes was minimal.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17594994     DOI: 10.1300/J069v26n02_03

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  21 in total

1.  Opioid-abusing health care professionals: options for treatment and returning to work after treatment.

Authors:  Marvin D Seppala; Michael R Oreskovich
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

2.  Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.

Authors:  Jonathan D Savant; Declan T Barry; Christopher J Cutter; Michelle T Joy; An Dinh; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2012-07-06       Impact factor: 4.492

3.  A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment.

Authors:  Michael S Gordon; Frank J Vocci; Faye Taxman; Marc Fishman; Bikash Sharma; Thomas R Blue; Kevin E O'Grady
Journal:  Contemp Clin Trials       Date:  2019-02-20       Impact factor: 2.226

Review 4.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

5.  Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons.

Authors:  Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2010-07-03

Review 6.  The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.

Authors:  Kathleen M Carroll; Roger D Weiss
Journal:  Am J Psychiatry       Date:  2016-12-16       Impact factor: 18.112

7.  Buprenorphine shared medical appointments for the treatment of opioid dependence in a homeless clinic.

Authors:  Sara L Doorley; Cheryl J Ho; Elizabeth Echeverria; Charles Preston; Huy Ngo; Ahmad Kamal; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2016-11-29       Impact factor: 3.716

8.  The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders.

Authors:  Elizabeth C Saunders; Mark P McGovern; Chantal Lambert-Harris; Andrea Meier; Bethany McLeman; Haiyi Xie
Journal:  Am J Addict       Date:  2015-09-21

9.  Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.

Authors:  George E Woody; Sabrina A Poole; Geetha Subramaniam; Karen Dugosh; Michael Bogenschutz; Patrick Abbott; Ashwin Patkar; Mark Publicker; Karen McCain; Jennifer Sharpe Potter; Robert Forman; Victoria Vetter; Laura McNicholas; Jack Blaine; Kevin G Lynch; Paul Fudala
Journal:  JAMA       Date:  2008-11-05       Impact factor: 56.272

10.  Consumer attitudes about opioid addiction treatment: a focus group study in New York City.

Authors:  Nancy L Sohler; Linda Weiss; James E Egan; Carolina M López; Jamie Favaro; Robert Cordero; Chinazo O Cunningham
Journal:  J Opioid Manag       Date:  2013 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.